By Dimitrios Kontos

AstraZeneca PLC (AZN.LN) said Monday that Imfinzi has received the approval of the U.S. Food and Drug Administration for the treatment of patients with a form of cell lung cancer.

Imfinzi is the only immunotherapy approved for patients with Stage 3 non-small cell lung cancer that cannot be removed via surgery, the London-listed pharmaceutical company said.

The approval is based on the study's results, which showed that Imfinzi can help prolong patients' lives, the company said.

The company also said until Imfinzi, patients had no FDA-approved treatment options after chemoradiation therapy.

Write to Dimitrios Kontos at dimitrios.kontos@dowjones.com

(END) Dow Jones Newswires

February 19, 2018 02:36 ET (07:36 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Astrazeneca